Sign up
Pharma Capital

VentriPoint Diagnostics reports that its new approved heart technology being used by internationally renowned pediatric cardiologist

Earlier this week, the firm said its VMS+ software had been approved for analyzing 3D echo images
The firm's tech is being used by a renowned pediatric cardiologist (not pictured)

Medtech group VentriPoint Diagnostics Ltd (CVE:VPT) gave another operational update on Tuesday, saying its VMS+ technology for the heart was now being used for analysis of the left ventricle as well as the right by an internationally renowned pediatric cardiologist in Germany.

As reported earlier this week, Ventripoint extended its reach into the heart imaging market as it revealed its VMS+ software had been approved for analyzing 3D echo images generated by any commercially available 3D echocardiography system.

READ: VentriPoint Diagnostics' heart monitoring tech further boosted by agreement with Canadian government

Renowned Dr Kai Thorsten Laser has now begun using the VMS+ software for 3-D echo analysis of the left ventricle at the HDZ NRW Heart and Diabetes Center in Germany, the firm said in a regulatory release Tuesday.

"We have experienced very positive results and accuracy using Ventripoint's VMS+ system on the right ventricle," said Dr Thorsten Laser.

"We now look forward to performing 3D analysis to validate accuracy of volumes of the left ventricle and in turn, improve cardiac patient care," he added.

Now that the company's software has been approved for all four chambers of the heart, the hospital will be using the Ventripoint VMS+ system for left ventricular volume analysis, particularly for pediatric patients.

There are many potential applications for this innovative technology, the firm says, which provides confidence in the volumetric measurements of patients with accuracy comparable to cardiac MRI.

Shares in Toronto were unchanged at $0.185.

Contact Giles Gwinnett at [email protected]

Follow Giles on Twitter @Gile74


Register here to be notified of future VPT Company articles
View full VPT profile View Profile
View All

Related Articles

cancer scan
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.